Henry Meds vs LillyDirect (Zepbound) (2026): prices, structure, verdict

On tirzepatide, Henry Meds↗ is cheaper: $349 versus $449 a month all-in — a $100 monthly gap, $1,200 across a year of maintenance dosing, and Henry Meds's figure is dose-flat while LillyDirect (Zepbound)↗'s structure is not.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, only Henry Meds has a rankable figure: $179 a month all-in; LillyDirect (Zepbound) does not offer semaglutide.

§ Side by side

§ Each record, read aloud

The two records, condensed

Henry Meds: the record, condensed

Henry Meds’s tirzepatide program bills $349 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #10 of 17 in the verified tirzepatide index — $134/month above the floor (NexLife↗, $215) — and sits $100 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $4,188.

On semaglutide, the number that matters at Henry Meds is $179 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $179 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #9 of 20 verified programs, with the floor $46/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $170 a month. A year at this figure: $2,148 monthly-billed.

Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗

LillyDirect (Zepbound): the record, condensed

On tirzepatide, the number that matters at LillyDirect (Zepbound) is $449 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The structure is tiered: the advertised entry point is $299, but the maintenance figure — the one a full year is actually billed at — is $449. That $150 gap between the ad and the anniversary is the single most important line in this record.

There is no membership line. $449 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #0 of 17 in the verified tirzepatide index — $234/month above the floor (NexLife, $215) — and sits $0 over the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $5,388.

Operationally at LillyDirect (Zepbound): shipping included (or same-day retail pickup); commitment 45-day refill cadence to keep pricing; cancellation no subscription; refill-window rules apply; pharmacy named (Eli Lilly direct / retail partners); states: 50 states; evidence source-verified, captured 2026-08-09. The full record with source and archive links: the LillyDirect (Zepbound) page · visit LillyDirect (Zepbound) ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $349 (Henry Meds) against $449 (LillyDirect (Zepbound)). $100 a month sounds survivable; $1,200 a year is a decision.

Structure sharpens the gap: Henry Meds’s figure is dose-flat (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill the same), while LillyDirect (Zepbound)’s is not — so Henry Meds’s number is a ceiling and LillyDirect (Zepbound)’s advertised entry ($299) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

Translate the $100/month spread into medication: $1,200 a year equals roughly 3.4 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: Henry Meds $349/mo month-to-month versus LillyDirect (Zepbound) $449/mo month-to-month. Same winner on both bases — Henry Meds leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Henry Meds $1,047 monthly; LillyDirect (Zepbound) $1,347 monthly — best path favors Henry Meds by $300. 6 months: Henry Meds $2,094 monthly; LillyDirect (Zepbound) $2,694 monthly — best path favors Henry Meds by $600. 12 months: Henry Meds $4,188 monthly; LillyDirect (Zepbound) $5,388 monthly — best path favors Henry Meds by $1,200. 24 months: Henry Meds $8,376 monthly; LillyDirect (Zepbound) $10,776 monthly — best path favors Henry Meds by $2,400.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

§ Structure vs structure

Everything besides the price

Coverage: Henry Meds publishes “most states”; LillyDirect (Zepbound) publishes “50 states” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: LillyDirect (Zepbound) names its network (Eli Lilly direct / retail partners); Henry Meds does not, which shifts the burden of verification onto your intake questions.

Exit terms: Henry Meds — none month-to-month; check terms before prepaying. LillyDirect (Zepbound) — 45-day refill cadence to keep pricing; no subscription; refill-window rules apply.

Evidence: Henry Meds third-party reported (captured 2026-08-05); LillyDirect (Zepbound) source-verified (2026-08-09).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

§ If you move

Switching between Henry Meds and LillyDirect (Zepbound)

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Henry Meds: check terms before prepaying; LillyDirect (Zepbound): no subscription; refill-window rules apply) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings